Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 May 24;9(5):e028832.
doi: 10.1136/bmjopen-2018-028832.

Randomised, placebo-controlled, double-blind, double-dummy, multicentre trial comparing electronic cigarettes with nicotine to varenicline and to electronic cigarettes without nicotine: the ECSMOKE trial protocol

Ivan Berlin  1   2 , Bertrand Dautzenberg  1 , Blandine Lehmann  3 , Jessica Palmyre  4 , Emmanuelle Liégey  5 , Yann De Rycke  6 , Florence Tubach  6   7
Affiliations
Randomized Controlled Trial

Randomised, placebo-controlled, double-blind, double-dummy, multicentre trial comparing electronic cigarettes with nicotine to varenicline and to electronic cigarettes without nicotine: the ECSMOKE trial protocol

Ivan Berlin et al. BMJ Open. .

Abstract

Introduction: Electronic cigarettes (EC) mainly with nicotine content are widely used worldwide. Although the number of publications about its use is increasing exponentially, evidence-based, unbiased, conclusive, head-to-head comparisons about its efficacy and safety as an aid for smoking cessation are lacking. METHODS AND ANALYSIS: Design: randomised, placebo and reference treatment-controlled, multicentre, double-blind, double-dummy, parallel-group trial. Participants: smokers smoking at least 10 cigarettes/day in the past year and motivated to quit, aged 18-70 years. Interventions: (A) EC without nicotine (ECwoN) plus placebo tablets of varenicline administered by oral route: placebo condition, (B) EC with nicotine (ECwN) plus placebo tablets of varenicline: ECwN condition. Voltage regulated EC will be used with liquid containing 12 mg/mL of nicotine for ad libitum use. Flavour: blond tobacco. (C) Reference: ECwoN plus 0.5 mg varenicline tablets: varenicline condition. Varenicline administered according to the marketing authorisationauthorisation. Treatment duration: 1 week+3 months. Primary outcome: continuous smoking abstinence rate (CAR) (abstinence from conventional/combustible cigarettes) during the last 4 weeks (weeks 9-12) of the treatment period defined as self-report of no smoking during the previous 2 weeks and expired air carbon monoxide ≤8 at visit 4 at week 10 after target quit date (TQD), that is, 11 weeks after treatment initiation AND at visit 5, week 12 after TQD, that is, 13 weeks after treatment initiation. Secondary outcomes: safety profile; point prevalence abstinence rate; CAR confirmed by urinary anabasine concentration; changes in cigarettes/day consumption; craving for tobacco and withdrawal symptoms with respect of baseline.

Ethics and dissemination: The ethics committee approval was obtained on 17 April 2018. All data collected about the study participants will be anonymised. Investigators will communicate trial results to participants, health authorities, healthcare professionals, the public and other relevant groups without any publication restrictions.

Trial registration number: NCT03630614; Pre-results.

Keywords: electronic cigarettes; randomised, controlled, double dummy trial; smoking cessation; varenicline.

PubMed Disclaimer

Conflict of interest statement

Competing interests: IB reports occasional honoraria from Pfizer in the last 3 years for counseling and presentations at meetings. FT is head of the clinical research unit of Pitié-Salpêtrière and Charles Foix hospitals and the pharmacoepidemiology center of Assistance Publique Hôpitaux de Paris, that have received research funding, grants and fees for consultant activities from a large number of pharmaceutical companies, that have contributed indiscriminately to the salaries of its employees. She did not receive any personal remuneration from these companies.

Figures

Figure 1
Figure 1
The ECSMOKE trial’s outline.
See this image and copyright information in PMC

References

    1. WHO. Tobacco Free Initiative. http://www.who.int/tobacco/health_priority/en/ (Accessed 10 Sep 2018).
    1. Doll R, Peto R, Boreham J, et al. . Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004;328:1519 10.1136/bmj.38142.554479.AE - DOI - PMC - PubMed
    1. Jha P, Ramasundarahettige C, Landsman V, et al. . 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med 2013;368:341–50. 10.1056/NEJMsa1211128 - DOI - PubMed
    1. Jha P, Peto R. Global effects of smoking, of quitting, and of taxing tobacco. N Engl J Med 2014;370:60–8. 10.1056/NEJMra1308383 - DOI - PubMed
    1. Holford TR, Meza R, Warner KE, et al. . Tobacco control and the reduction in smoking-related premature deaths in the United States, 1964-2012. JAMA 2014;311:164–71. 10.1001/jama.2013.285112 - DOI - PMC - PubMed

Publication types

Associated data